Literature DB >> 17360461

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.

Padmanee Sharma1, Yu Shen, Sijin Wen, Sachiko Yamada, Achim A Jungbluth, Sacha Gnjatic, Dean F Bajorin, Victor E Reuter, Harry Herr, Lloyd J Old, Eiichi Sato.   

Abstract

Tumor-infiltrating cytotoxic T lymphocytes (TILs), including CD8 TILs, have been associated with favorable clinical outcomes in multiple tumor types. Tumor-infiltrating CD8 T cells and major histocompatibility complex (MHC) class I expression in urothelial carcinoma (UC) have not been previously reported. Most immune responses are mediated by local cytotoxic lymphocytes (CD8 T cells), which can eradicate tumor cells by recognizing tumor-associated antigens presented by MHC class I molecules. Here we analyzed the presence of intratumoral CD8 T cells, the expression of MHC class I antigen, and the expression of the NY-ESO-1 tumor antigen in UC samples and correlated our findings with clinical outcome. Immunohistochemical staining for intratumoral CD8 T cells in tissue samples from 69 patients with UC showed that patients with advanced UC (pT2, pT3, or pT4) and higher numbers of CD8 TILs within the tumor (> or =8) had better disease-free survival (P < 0.001) and overall survival (P = 0.018) than did patients with similar-staged UC and fewer intratumoral CD8 TILs. We conclude that the extent of intratumoral CD8 TILs is an important prognostic indicator in advanced UC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360461      PMCID: PMC1820692          DOI: 10.1073/pnas.0611618104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Expression of b 4 and b 5 chi light chain allotypes by B and pre-B cells in allotype-suppressed and neutralized b4b5 rabbits.

Authors:  M A Simons; A R Hayward; W E Gathings; A R Lawton; G O Young-Cooper; M D Cooper; R G Mage
Journal:  Eur J Immunol       Date:  1979-11       Impact factor: 5.532

2.  Peptide Vaccination in Clinical Oncology.

Authors:  E. Jäger; D. Jäger; A. Knuth
Journal:  Onkologie       Date:  2000-10

3.  Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.

Authors:  T Nishiyama; M Tachibana; Y Horiguchi; K Nakamura; Y Ikeda; K Takesako; M Murai
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

4.  Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy.

Authors:  R Mendez; A Serrano; E Jäger; I Maleno; F Ruiz-Cabello; A Knuth; F Garrido
Journal:  Tissue Antigens       Date:  2001-06

5.  Identification of cancer/testis genes by database mining and mRNA expression analysis.

Authors:  Matthew J Scanlan; Claudia M Gordon; Barbara Williamson; Sang-Yull Lee; Yao-Tseng Chen; Elisabeth Stockert; Achim Jungbluth; Gerd Ritter; Dirk Jäger; Elke Jäger; Alexander Knuth; Lloyd J Old
Journal:  Int J Cancer       Date:  2002-04-01       Impact factor: 7.396

6.  Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma.

Authors:  Padmanee Sharma; Yu Shen; Sijin Wen; Dean F Bajorin; Victor E Reuter; Lloyd J Old; Achim A Jungbluth
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

7.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

8.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

9.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

Authors:  Ian D Davis; Weisan Chen; Heather Jackson; Phillip Parente; Mark Shackleton; Wendie Hopkins; Qiyuan Chen; Nektaria Dimopoulos; Tina Luke; Roger Murphy; Andrew M Scott; Eugene Maraskovsky; Grant McArthur; Duncan MacGregor; Sue Sturrock; Tsin Yee Tai; Simon Green; Andrew Cuthbertson; Darryl Maher; Lena Miloradovic; Susan V Mitchell; Gerd Ritter; Achim A Jungbluth; Yao-Tseng Chen; Sacha Gnjatic; Eric W Hoffman; Lloyd J Old; Jonathan S Cebon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-13       Impact factor: 11.205

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  203 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  Immunotherapies for bladder cancer: a new hope.

Authors:  Farhad Fakhrejahani; Yusuke Tomita; Agnes Maj-Hes; Jane B Trepel; Maria De Santis; Andrea B Apolo
Journal:  Curr Opin Urol       Date:  2015-11       Impact factor: 2.309

3.  High CD4⁺ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer.

Authors:  Qinglei Zhang; Chongli Hao; Guangzhou Cheng; Lei Wang; Xiang Wang; Chang Li; Juhui Qiu; Kejia Ding
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 4.  Muscle-invasive urothelial bladder cancer: an update on systemic therapy.

Authors:  Hayley Knollman; J Luke Godwin; Rishi Jain; Yu-Ning Wong; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Ther Adv Urol       Date:  2015-12

5.  Score Estimating Equations from Embedded Likelihood Functions under Accelerated Failure Time Model.

Authors:  Jing Ning; Jing Qin; Yu Shen
Journal:  J Am Stat Assoc       Date:  2014-10       Impact factor: 5.033

Review 6.  The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

Authors:  Nick van Dijk; Samuel A Funt; Christian U Blank; Thomas Powles; Jonathan E Rosenberg; Michiel S van der Heijden
Journal:  Eur Urol       Date:  2018-09-28       Impact factor: 20.096

7.  Claudin-low bladder tumors are immune infiltrated and actively immune suppressed.

Authors:  Jordan Kardos; Shengjie Chai; Lisle E Mose; Sara R Selitsky; Bhavani Krishnan; Ryoichi Saito; Michael D Iglesia; Matthew I Milowsky; Joel S Parker; William Y Kim; Benjamin G Vincent
Journal:  JCI Insight       Date:  2016-03-17

8.  Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.

Authors:  Randy F Sweis; Stefani Spranger; Riyue Bao; Gladell P Paner; Walter M Stadler; Gary Steinberg; Thomas F Gajewski
Journal:  Cancer Immunol Res       Date:  2016-05-17       Impact factor: 11.151

9.  Cyclin-dependent kinase inhibitors block leukocyte adhesion and migration.

Authors:  Li Liu; Barbara Schwartz; Yoshiaki Tsubota; Elaine Raines; Hiroaki Kiyokawa; Karyn Yonekawa; John M Harlan; Lynn M Schnapp
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

10.  The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results.

Authors:  Ismail Selvi; Umut Demirci; Nazan Bozdogan; Halil Basar
Journal:  Int Urol Nephrol       Date:  2019-09-20       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.